Why Amgen Investors Should Pay Attention to This

By Naomi Wentworth • Wednesday, February 07 09:52 • Permanent Link

One of the losers of today's trading session was Amgen. Shares of the Biotechnology company plunged -3.1%, and some investors may be wondering if its price of $306.27 would make a good entry point. Here's what you should know if you are considering this investment:

Amgen has moved 31.6% over the last year, and the S&P 500 logged a change of 20.3%
AMGN has an average analyst rating of buy and is 10.69% away from its mean target price of $276.7 per share
Its trailing earnings per share (EPS) is $14.06
Amgen has a trailing 12 month Price to Earnings (P/E) ratio of 21.8 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $19.98 and its forward P/E ratio is 15.3
The company has a Price to Book (P/B) ratio of 26.29 in contrast to the S&P 500's average ratio of 2.95
Amgen is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
AMGN has reported YOY quarterly earnings growth of -52.6% and gross profit margins of 0.7%
The company has a free cash flow of $-359249984, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.